Clal Insurance Enterprises Holdings Ltd cut its holdings in shares of Mylan NV (NASDAQ:MYL) by 6.3% during the 4th quarter, HoldingsChannel reports. The fund owned 1,012,628 shares of the company’s stock after selling 68,200 shares during the period. Clal Insurance Enterprises Holdings Ltd’s holdings in Mylan were worth $27,746,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the business. Sphera Funds Management LTD. lifted its holdings in shares of Mylan by 26.6% in the fourth quarter. Sphera Funds Management LTD. now owns 1,677,241 shares of the company’s stock valued at $45,956,000 after purchasing an additional 352,241 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Mylan by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock valued at $215,460,000 after purchasing an additional 1,026,731 shares in the last quarter. Kinneret Advisory LLC bought a new stake in shares of Mylan in the fourth quarter valued at about $71,000. Fort L.P. bought a new stake in shares of Mylan in the fourth quarter valued at about $92,000. Finally, ARP Americas LP bought a new stake in shares of Mylan in the fourth quarter valued at about $263,000. Hedge funds and other institutional investors own 83.01% of the company’s stock.
A number of brokerages have recently commented on MYL. UBS Group restated a “neutral” rating and issued a $31.00 price target on shares of Mylan in a report on Thursday, March 7th. Zacks Investment Research lowered Mylan from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 6th. Credit Suisse Group restated a “buy” rating and issued a $37.00 price target on shares of Mylan in a report on Wednesday, March 6th. Morgan Stanley upgraded Mylan from an “equal weight” rating to an “overweight” rating and set a $35.00 price target on the stock in a report on Wednesday, March 6th. They noted that the move was a valuation call. Finally, Wells Fargo & Co cut their price target on Mylan from $40.00 to $33.00 and set an “outperform” rating on the stock in a report on Wednesday, February 27th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. Mylan presently has an average rating of “Buy” and a consensus target price of $40.72.
Mylan (NASDAQ:MYL) last released its earnings results on Tuesday, February 26th. The company reported $1.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by ($0.06). Mylan had a return on equity of 19.06% and a net margin of 3.08%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.10 billion. During the same quarter in the previous year, the company posted $1.43 EPS. The business’s revenue was down 4.8% on a year-over-year basis. Equities research analysts predict that Mylan NV will post 4.38 EPS for the current year.
In other Mylan news, insider Paul Campbell sold 11,533 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $27.50, for a total transaction of $317,157.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.81% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Recommended Story: What is dollar cost averaging (DCA)?
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.